anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND/OBJECTIVES: Parenteral nutrition (PN) can be standardized or customized according to a patient's individual needs, including clinical, metabolic, nutritional, and inflammatory conditions. The influence of inflammation on the indication of standard or customized PN for adolescents hospitalized in a quaternary hospital in the southeastern of Brazil was evaluated.
METHODS: A historical cohort study of 61 adolescents admitted to the hospital was conducted. Nutritional, clinical, and biochemical data from the first 7 days of PN use were analyzed. Elevated serum mineral and triglyceride levels, as well as renal or liver failure (grade III or IV), were considered unequivocal reasons for PN customization, while restoring energy-protein adequacy and low serum mineral levels were considered questionable reasons. Inflammatory status was analyzed during the study period.
RESULTS: A total of 128 PN solutions were prescribed, comprising 55 standardized and 73 customized. Overall, 40/61 patients required customized PN. The main reason for customization was to restore energy-protein adequacy (n = 48), while 24.7% (n = 18) of individualizations were for unequivocal reasons. Restoring energy-protein adequacy in the first 48 h was shown to have contributed to high transthyretin, which reduced the need for additional customized PN (r = -0.544; p = 0.044). A positive correlation was found between the total number of PN readjustments and C-Reactive Protein levels (r = 0.509; p = 0.044).
CONCLUSIONS: Conditions such as malnutrition or an inflammatory state in adolescents presenting metabolic changes are indications for the use of customized PN.
The present invention relates to a wet tissue and, more particularly, to a wet tissue capable of having an antimicrobial function for super bacteria with an antimicrobial aqueous solution, which is a non-preservative natural mineral component (ESN substance) diluent. The wet tissue according to the present invention is formed by a fabric absorbing the antimicrobial aqueous solution. The antimicrobial aqueous solution is a natural mineral component (ESN substance) diluted by a factor of approximately 100 to 1,000. The antimicrobial aqueous solution is excellent in terms of antimicrobial activity and has a sterilization, microorganism removal, or antimicrobial effect of at least 90% with respect to super bacteria. Preferably, the wet tissue fabric is made from a pulp material or a non-woven fabric. Depending on embodiments, however, it may be made from a fiber material such as cotton. The configuration of the fabric according to the present invention may be rayon 50% + PET 50% or rayon 60% + PET 40% or rayon 70% + PET 30%.
A complex of an anionic polysaccharide with silver. The complex is preferably a salt formed between the polysaccharide and Ag<+> and the anionic polysaccharide is preferably a polycarboxlate. The anionic polysaccharide may be selected from alginates, hyaluronates, pectins, carageenans, xanthan gums, sulfated dextrans, cellulose derivatives, oxidised celluloses and mixtures thereof. Also claimed is a wound dressing, such as a sponge sheet, a woven or non-woven fabric, or a gel sheet, comprising a complex of an anionic polysaccharide with silver for treating ulcers. The wound dressing may further comprise collagen and preferably also comprises oxidised regenerated cellulose. Also claimed is the use of the aforementioned complex for the preparation of a medicament for the treatment of wounds and a method of making the complex comprising the step of treating an anionic polysaccharide with a solution of a silver salt.
Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session. Prior to training, strength and proprioception exercises will be performed.
BACKGROUND: There is growing interest in extended antibiotic prophylaxis (EAP) following total joint arthroplasty (TJA); however, the benefit of EAP remains controversial. For this investigation, both oral and intravenous antibiotic protocols were included in the EAP group.
METHODS: The Cochrane Database of Systematic Reviews, Cochrane Register of Controlled Trials, PubMed, MEDLINE, Web of Science, Ovid Embase, Elton B. Stephens CO, and Cumulative Index to Nursing and Allied Health Literature were queried for literature comparing outcomes of primary and aseptic revision total hip arthroplasty (THA) and total knee arthroplasty (TKA) patients who were treated with either ≤24 hours of postoperative antibiotic prophylaxis (standard of care [SoC]) or >24 hours of EAP. The primary outcome was periprosthetic joint infection (PJI). A pooled relative-risk random-effects Mantel-Haenszel model was implemented to compare cohorts.
RESULTS: There were 18 studies with a total of 19,153 patients included. There was considerable variation in antibiotic prophylaxis protocols with first-generation cephalosporins being the most commonly implemented antibiotic for both groups. Patients treated with EAP were 35% less likely to develop PJI relative to the SoC (P = .0004). When examining primary TJA, patients treated with EAP were 39% and 40% less likely to develop a PJI for TJA (P = .0008) and THA (P = .02), respectively. There was no significant difference for primary TKA (P = .17). When examining aseptic revision TJA, EAP led to a 36% and 47% reduction in the probability of a PJI for aseptic revision TJA (P = .007) and aseptic revision TKA (P = .008), respectively; there was no observed benefit for aseptic revision THA (P = .36).
CONCLUSIONS: This meta-analysis demonstrated that patients treated with EAP were less likely to develop a PJI relative to those treated with the SoC for all TJA, primary TJA, primary THA, aseptic revision TJA, and aseptic revision TKA. There was no significant difference observed between EAP and SoC for primary TKA or aseptic revision THA.
Visit 1: sign consent form, pregnancy tests for females, resting blood pressure, height/weight, body composition, and VO2max test. Visit 2: 1-repetition maximum (RM) test and protocol familiarization. Visit 3: perform a muscle-damaging exercise protocol. Pre-exercise soreness and blood samples will be collected. After, they will perform the pre-exercise testing to assess baselines levels of power and sprint times. Upon completion, they will undergo the muscle-damaging exercise protocol. Post-exercise blood samples and soreness will be collected. The participant will then be given either placebo or CBD cream to rub into their quadriceps. Visit 4 \& 5: collect blood samples and soreness scale measurements. Participants will then be given the same treatment (placebo or CBD cream) as they had on visit 3. Visit 6 will be similar to visit 3, except the participant will be given the opposite treatment (placebo or CBD cream). Visits 7 \& 8 will be similar to visits 4 \& 5, respectively.
The prevalence of kidney stone disease in the United States is increasing. Recurrence of kidney stone disease has been reported as high as 50% at five years. Urine supersaturation is a predominant factor in the formation of crystallization and stone disease and is dependent on fluid volume. High fluid consumption that dilutes the urine has been shown both in vitro and in clinical studies to reduce the tendency for stone crystallization as well as effectively decrease stone recurrence. As a result, water intake greater than two liters per day is a common initial therapy for prevention of stone disease. However, studies have shown that despite physician counseling most patients are only able to modestly increase their urine volume through fluid intake. This finding may be due to a discrepancy in patient perception of their actual fluid intake and resulting urine volume. The purpose of this investigation is to prospectively evaluate the benefit of different methods of educating patient regarding their fluid intake through a readily available daily cellular phone application to improve overall urine output and reduce risk factors for stone recurrence.
A crystalline glucoside is prepared by extracting exhaustively either fresh or dried and remoistened leaves of digitalis, for example, digitalis lanata, with solvents immiscible with water such as methyl or ethyl acetate, methylethyl ketone, or chloroform, in the presence of readily soluble salts such as magnesium sulphate, sodium chloride, calcium chloride, ammonium sulphate, sodium nitrate, sodium nitrite, or primary sodium phosphate.  The extract is then evaporated at a low temperature in vacuo and the residue is treated with ether.  The insoluble precipitate formed, which contains the glucosides in the form of their tannoids, is separated by filtration, further treated with ether, and dissolved in an aqueous organic solvent such as an aqueous alcohol.  The solution is treated with tannin-precipitating substances such as lead hydroxide, thus liberating the glucosides. The precipitated tannin and other impurities are removed by filtration and the solution partly evaporated to drive off the alcohol causing the difficultly soluble portion of the glucosides to precipitate.  The precipitate is purified by recrystallization from a suitable solvent such as methyl alcohol.  Instead of dissolving the residue after treatment with ether directly in an aqueous solvent this residue may first be treated with water, which may contain a little sodium chloride, the subsequent treatment with the tannin-precipitation substances &c. being then carried out with the difficultly soluble portion of the residue only.
The vaccine will be made by mixing two kinds of cells: 1) some lung cancer cells, which have been grown in the lab, and 2) experimental "bystander (present but not taking part in the immune response)" cells. All the cells in the vaccine will be treated with high-dose X-rays to make sure that none of them grow and cause more cancer. The bystander cells are human cells that have been genetically changed to express GM-CSF and CD40L. These are called "GM.CD40L". (That is the original cells, called K562, with the genes for human GM-CSF and CD40L inserted into them). These changes are designed to help boost the participants' immune system to better fight the cancer in their body. GM-CSF is a hormone that is known to stimulate bone marrow to make more white blood cells.

CCL21 is a chemokine (protein) that helps to recruit T cells (a type of white blood cell that helps to protect the body from infections) and leads to hyper-responsive T cells. This leads to heightened immune responses when T cells are exposed to both CCL21 and antigen (a substance that when introduced into the body lead to production of an antibody)-presenting cells (A cell that can "present" antigen in a form that T cells can recognize it ). The induction of a strong cell-mediated immune response is the type of immunity expected to be most involved in controlling cancer cell growth. A randomized trial of a vaccine consisting of the GM.CD40L bystander cells and an equivalent number of allogeneic (taken from different individuals) tumor cells plus or minus CCL21 is proposed.
This was an open-label, balanced, randomised, two-treatment, two-period, two-sequence, single-dose crossover bioavailability study performed on 36 healthy adult male and female non-smoking or light smoking volunteers and 2 alternates. A total of 36 subjects completed the clinical phase of the study. In each period, subjects were housed from the evening before dosing until after the 24-hour blood draw. Single oral 1000 mg doses were separated by a washout period of 7 days Of the 36 healthy adult non-smoking or light-smoking (10 cigarettes/day) volunteers and 2 alternates (19 males, 19 non-pregnant females) enrolled in the study, two did not complete the clinical phase of the study. Subject No. 11 was withdrawn from the study by the on-duty Physician after a positive pregnancy test prior to dosing in Period 2 and Subject No. 20 was withdrawn from the study by the Clinical Study Manager after she failed to complete her breakfast prior to dosing in Period 2. Thus a total of 36 subjects completed the clinical phase of the study
In this study, patients with severe necrotizing pancreatitis will be followed prospectively throughout their hospital course (anticipated duration of hospitalization ranging between 4-8 weeks). If patients are suspected to have infection of pancreatic necrosis, they will be consented for enrollment. Patients will be determined by their attending physician to require either operative intervention or radiologic guided drainage of pancreatic necrosis and infected peripancreatic fluid. At the time of drainage procedure or intervention, one sample of peripancreatic fluid will be sent to the hospital's microbiology department for standard gram stain and bacterial culture identification and a second sample will be frozen for bacterial DNA analysis. Patients will be followed for the duration of their hospitalization for in hospital outcomes, mortality and final microbiology culture results. Samples will then be processed at six months and one year following sample collection for bacterial DNA deep sequencing analysis and will be compared to bacteria identified using standard culture technique.
Patients with obstructive sleep apnea (OSA) experience intermittent hypoxemia and arousal during sleep due to recurrent collapse of upper airway. Epidemiologic evidence showed they were at higher risk for autoimmune diseases. The regular T cell (Treg) has a crucial role in controlling autoimmunity. In this study, 40 OSA patients and 40 age-, gender- and BMI-matched controls will be recruited. Peripheral venous blood of the participants is drawn for numeration of CD4+CD25+FoxP3+ regular T cells by flow cytometry. As well, the CD4+CD25+ regular T cells are enriched by MACS and tested for their suppressive functions on proliferation assays. Th12+ CD4+ cells are also measured.
Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery. The first 9 participants in Arm A (atezolizumab monotherapy) will also receive adjuvant atezolizumab 16 weeks after standard of care surgery and radiation, or chemoradiation therapy, at a fixed dose of 1200 mg IV every 3 weeks for an additional 12 cycles.
1. A compound of formula (I):   in which R is residue of carboxylic acid having upto 18 carbon atoms. 2. A compound of formula (I) according to claim 1, in which R is acetyle. 3. A method for preparing compounds of formula (I) according to claim 1 or 2, wherein a compound of formula (II):   in which R has a value as defined hereinbefore is subjected to the action of sulfonic acid and then to a base selected from diazabicycloundecene, diazabicyclononene, 2,6-lutidine, 2,4,6-collidine or tetramethylguandine to obtain a compound of formula (III):   which is subjected to the action of carbonyldiimidazole, then to NH2NH2 hydrazine to obtain a corresponding compound of formula (I). 4. A compound of formula (III) according to claim 3 as intermediate products to obtain compounds of formula (I). 5. A compound of formula (III) according to claim 4, wherein R is acetyle. 6. A method for preparing compounds of formula (VIII):   wherein R'1 is a hydrogen atom or a hydrocarbon radical having upto 23 carbon atoms, saturated or unsaturated, which can be interrupted by one or several heteroatoms and can carry one or several functional groups, wherein a compound of formula (I):   in which R is residue of carboxylic acid having ipto 18 carbon atoms is subjected to the action of an agent cleaving protected hydroxy groups to obtain a compound of formula (IV):   which is subjected to the action of aldehyde of formula (V):   in which R'1 has a value as defined hereinbefore to obtain a compound of formula (VI):   which is subjected to the action of diimide in the presence of dimethylsulfoxide for hydroxyle oxidation in position 3, then to the action of an agent cleaving hydroxyle  in position 2' to obtain a compound of formula (VII):   which is subjected to the action of a reducer to obtain a corresponding compound of formula (VIII), in which R'1 is a radical.
The study will include diabetes patients diagnosed within 1 year (including 1 year) from both inpatient and outpatient medical record systems between January 2022 and December 2022. Each center enrolls approximately 1000 new diabetes patients annually, and it is planned to include 30 centers, with an estimated total of 30,000 participants.
Functional dyspepsia is a common functional disorder of the gastrointestinal tract that is responsible for many primary care visits. No organic changes have been found to explain its symptoms. We hypothesize that modern lifestyles and environmental factors, especially psychological stress, play a crucial role in the high prevalence of functional dyspepsia and metabolic syndrome. While gastrointestinal tract diseases are rarely linked to metabolic disorders, chronic stress, obesity-related metabolic syndrome, chronic inflammation, intestinal dysbiosis, and functional dyspepsia have significant pathophysiological associations. Functional dyspepsia, often associated with anxiety and chronic psychological stress, can activate the neuroendocrine stress axis and immune system, leading to unhealthy habits that contribute to obesity. Additionally, intestinal dysbiosis, which is commonly present in functional dyspepsia, can exacerbate systemic inflammation and obesity, further promoting metabolic syndrome-related disorders. It is worth noting that the reverse is also true: obesity-related metabolic syndrome can worsen functional dyspepsia and its associated symptoms by triggering systemic inflammation and intestinal dysbiosis, as well as negative emotions (depression) through the brain-gut axis. To understand the pathophysiology and deliver an effective treatment strategy for these two difficult-to-cure disorders, which are challenging for both caregivers and patients, a psychosocial paradigm is essential.
PURPOSE:To obtain an anticancer agent containing phospholipid or diacylglycerol as an active ingredient. CONSTITUTION:A phospholipid (e.g. phosphatidyl choline, phosphatidyl serine or phosphatidyl inositol) or diacylglycerol (e.g. dilinoleoylglycelol or 1-oleoyl-2- acetylglycerol) is incorporated as an active ingredient to provide the aimed anticancer agent. Liposome of the phospholipid is at first prepared by subjecting the phospholipid dried in a nitrogen gas stream to supersonic treatment in a phosphoric acid buffer containing no Ca<2+> and Mg<2+> in order to prepare the aimed agent. The preparation is sufficiently carried out at a treating temperature of 25 deg.C and treating time of about 60sec. The anticancer agent brings innovative progress to remedy for cancer of the lung which has been short of good treating method so far, but the agent is not limited to only cancer of the lung.
The application discloses an application of Drp protein in preparing an anti-tumor medicament, and relates to the technical field of biological medicines. The application provides an application of Drp protein in preparing an anti-tumor medicament, wherein the Drp protein is as follows: a) An amino acid sequence shown in SEQ ID NO. 1; or b) a polypeptide fragment lacking at least one amino acid in the amino acid sequence shown in SEQ ID NO. 1; or c) polypeptide obtained by phosphorylation or acetylation modification of the polypeptide with the amino acid sequence shown in SEQ ID NO. 1. Experiments prove that the Drp1 protein has remarkable anti-tumor activity, in particular to anti-liver cancer ascites tumor activity. The application not only provides a new source for preparing anti-tumor medicines, but also discovers a new medicinal value of Drp protein.
Cold snare polypectomy; Polyp size will be measured using the tip of the snare catheter (2.5mm). Large (10-15 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, 4 biopsies will be performed from all four quadrants of resection margins.
Headache and neurological deficits with cerebrospinal fluid (CSF) lymphocytosis (HaNDL) is a rare condition characterised by recurrent episodes of headache and transient neurological deficits. This case report presents a young patient initially diagnosed with hemiplegic migraine, having a normal brain CT, with focal cerebral perfusion mismatch not restricted to a single vascular territory on CT angiography. Brain MRI revealed a cytotoxic lesion of the splenium in the corpus callosum (CLOCC), a feature also reported in migraine. However, recurrent headaches with neurological deficits prompted further investigations with CSF analysis and brain MRI, confirming HaNDL and demonstrating reversibility of CLOCC. Recognising HaNDL as a differential diagnosis is essential in patients with recurrent headaches with focal neurological deficits, given the differences in therapeutic approach. The relationship between migraine and HaNDL is not fully understood, but they may share a pathophysiological link. Awareness of this is crucial for accurate diagnosis.
This is a prospective, interventional, non-randomized, worldwide, multi-center trial. A maximum of 1300 subjects were to be implanted at a maximum of 40 sites in the US, Europe and Canada. The trial includes male and female patients of legal age to provide informed consent in the country where they enrolled in the trial, requiring replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic valve. Subjects are followed out to 5 years, and select sites follow subjects out to 12 years. Enrollment closed on 14Jul2017 for all valve sizes. Enrollment was reopened in Apr2019 for the 29mm valve size at a subset of US and Canadian sites to obtain greater patient numbers required by the FDA to support US commercial approval of this valve size. Enrollment for the 29mm valve size closed on 14Feb2023.
The control group underwent US-guided sham block at L4 vertebrae level with 20 ml of saline 0.9%. At the level of L4 and after skin sterilization, sham block was administered in a sitting position. Hydro dissection of the interfascial plane between the erector spinae muscle and TP was confirmed by visualizing the local anesthetic spreading in a linear pattern between the muscle and the bony acoustic shadows of the TP. Then, up to 20 ml Saline 0.9% was injected.
PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.
The present invention relates to acetazolamide microemulsion as eyedrops for treating glaucoma. The present invention is prepared from acetazolamide, laurocapram, tween-80, mannitol, boracic acid and polyvinylpyrrolidone. A preparation technology of the present invention comprises the following steps: distilled water is added to the laurocapram, the tween-80, the mannitol and the boracic acid, an obtained mixture is emulsified into microemulsion solvent in an ultrasonic emulsification mode, and the microemulsion solvent is sterilized and sealed into a bottle; acetazolamide powder, sodium hydroxide and distilled water are used for preparing sodium salt of acetazolamide; the polyvinylpyrrolidone and the mannitol are added, an obtained mixture is pressed into tablets, and the tablet is sealed in a bottle cap; when the present invention is used, the tablet is dissolved in the microemulsion solvent, and the present invention can be obtained. The laurocapram is added to the present invention, which leads the permeability of an acetazolamide opposite angle membrane to be increased by 39.7 times. When the present invention is used for one time, the intraocular tension can be lowered by 8 mmHg. The toxic side effect caused by oral administration of acetazolamide is avoided.